JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265745

Human ERGIC2 (PTX1) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ERGIC2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)
  • Sanger seq

Unknown

Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)

Allele-3 : Insertion of the selection cassette in exon 2.

Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)
  • Sanger seq

Unknown

Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)

Allele-2 : 0 bp insertion in exon 2.

Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)
  • Sanger seq

Unknown

Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell line (AB265745)

Allele-1 : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265745-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265745 Human ERGIC2 (PTX1) knockout HeLa cell line", "number":"AB265745-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265745-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265745-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265745-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265745 Human ERGIC2 (PTX1) knockout HeLa cell line", "number":"AB265745-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265745-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265745 Human ERGIC2 (PTX1) knockout HeLa cell line", "number":"AB265745-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265745-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265745 Human ERGIC2 (PTX1) knockout HeLa cell line", "number":"AB265745-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ERGIC2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ERGIC2 also known as PTX1 is involved in transport and processing within the endoplasmic reticulum-Golgi intermediate compartment. ERGIC2 has a mass of approximately 45 kDa. It is an integral membrane protein widely expressed in various tissues and particularly prominent in the liver and kidney. This protein plays a significant role in regulating the trafficking of proteins between the endoplasmic reticulum and the Golgi apparatus important for proper cellular function.
Biological function summary

ERGIC2 contributes to the maintenance of the cellular infrastructure by facilitating the efficient transport of proteins. It is an essential component of the early secretory pathway and plays a role in protein sorting and vesicle formation. ERGIC2 participates in a well-defined protein complex associated with COPII-coated vesicles which aid in cargo transport from the endoplasmic reticulum to the Golgi. Its interaction within this complex highlights its importance in cellular logistics and management.

Pathways

ERGIC2 participates actively in the ER-Golgi transport pathway and the secretory pathway. These pathways are essential for efficient protein trafficking and processing. ERGIC2 interacts with other proteins such as COPII components including SEC23 and SEC24 which are integral to the formation of transport vesicles. These interactions highlight how ERGIC2 fits into larger pathways that ensure cellular homeostasis and functionality.

Alterations in ERGIC2 expression have been observed in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Insufficient or excess ERGIC2 can impair protein trafficking leading to cellular stress and disease progression. Its role in these disorders bridges it to proteins like APP (Amyloid precursor protein) in Alzheimer's disease potentially affecting amyloid processing and aggregation. Understanding ERGIC2's function may offer insights into therapeutic strategies for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com